---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-221756"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2025-09-29T23:59:59+00:00"
generated_at: "2026-05-17T05:25:33.887997+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Climb Bio reports CLYM116 preclinical data showing >70% IgA reduction and longer half-life vs sibeprenlimab

## Summary
- In nonhuman primate study, CLYM116 showed ~2-3 times longer half-life and deeper IgA reduction vs sibeprenlimab at 6 mg/kg.
- Subcutaneous CLYM116 demonstrated ~85% bioavailability and favorable tolerability in the NHP study.
- CLYM116 Phase 1 trial in healthy volunteers expected to start Q4 2025 with initial data mid-2026.
- CLYM116 is the only known 'sweeper' anti-APRIL monoclonal antibody in development for IgA nephropathy.
- Updated KDIGO 2025 guideline highlights need for more active IgAN management, expanding potential market.

## SEC filing metadata
- accession: 0001193125-25-221756
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2025-09-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312525221756/0001193125-25-221756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312525221756/d942245d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-221756
- JSON: https://secwatch.observer/filing/0001193125-25-221756.json
- Plain text: https://secwatch.observer/filing/0001193125-25-221756.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.